Challenges and opportunities in oral formulation development

American Pharmaceutical Review

Volumn 15, Issue 7, 2012, Pages

  Ali, Shaukat ^a   Kolter, Karl ^b  

^a BASF CORPORATION   (United States)

^b BASF SE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASTOR OIL; DIACYLGLYCEROL; DIETHYLENE GLYCOL MONOETHYL ETHER; ETRAVIRINE; EXCIPIENT; FATTY ACID; GRISEOFULVIN; ITRACONAZOLE; LOPINAVIR PLUS RITONAVIR; NABILONE; OCTANOIN; POLOXAMER; POLYMER; RITONAVIR; ROSUVASTATIN; SOLUBILIZER; SURFACTANT; TACROLIMUS; TELAPREVIR; TRIACYLGLYCEROL; VEMURAFENIB;

AQUEOUS SOLUTION; ARTICLE; DISPERSION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MELTING POINT; PH; QUALITY CONTROL; THERMOSTABILITY;

EID: 84874380417     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. C. Giliyar, D. T. Fikstad, S. Tyavanagimatt, "Challenges and opportunities in oral delivery of poorly water-soluble drugs". Drug Delivery Technol., 2006, 6, 57-63
2. J. Breitenbach, "Melt extrusion: from process to drug delivery technology", Eur. J. Pharm. Biopharm., 2002, 54, 107-117. (Pubitemid 34919382)
3. D. J. Hauss, "Oral lipid-based formulations: enhancing he bioavailability of poorly water soluble drugs", volume 170, Informa Healthcare.
4. P. P. Constantinides, "Enabling Oral Drug Delivery with Lipids: Trends and Perspectives". AAPS Workshop, Lipid-based delivery for improving drug absorption-Mechanistic Understanding and practical approaches, Baltimore, USA, 23-24 April 2012.
5. Li, P., Zhaob, L., Developing early formulations: Practice and perspective, Int. J. Pharm., 2007, 341, 1-19. (Pubitemid 47088122)
6. Mehta M. AAPS/FDA Workshop on bio-pharmaceutics classification system (2002).
7. J. Alsenz, M. Kansy, "High throughput solubility measurement in drug discovery and development", Adv. Drug Del. Rev., 2007;59:546-567. (Pubitemid 47285404)
8. B. Griffin, Advances in lipid-based formulations: Overcoming the challenges of low bioavailability for poorly water soluble drug compounds, Am. Pharm. Rev., March 2012, 41-47.
9. S. H. Yalkowsky, Solubility and Solubilization in Aqueous Media, Oxford University Press, NY (1999), p. 67.
10. S. S. Ren, B. D. Anderson, "What determines drugs solubility in lipid vehicles: Is it predictable?" Adv. Drug Del. Rev., 2008;60, 638-656.
11. T. Reintjes, "Solubility enhancement with BASF pharma polymers: Solubilizer compendium". BASF SE Pharma Ingredients & Services, Germany, October 2011.
12. de Smidt, C. P., Campanero, M. A., Trocóniz, I. F., "Intestinal absorption of penclomedine from lipid vehicles in the conscious rat: contribution of emulsification versus digestibility", Int. J. Pharm., 2004, 270, 109-118. (Pubitemid 38077092)
13. Mullertz, A., Ogbonna, A., Ren, S., Rades, T., New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs, J. Pharm. Pharmacol., 2010, 62, 1622-1636.
14. S. Ali, T. Rosen, "Rebranding of BASF Solubilizers", Tablets & Capsules, April 2012.
15. S. X. Cui, S. F. Nie, L. Li, C. G. Wang, W. S. Pan, J. P. Sun, "Preparation and evaluation of self-microemulsifying drug delivery system containing vinpocetine", Drug Dev. Ind. Pharm. 2009, 35, 603-11.
16. Shen, H. R., Zhong, M. K., Preparation and evaluation of self microemulsifying drug delivery systems (SMEDDS) containing atorvastatin., J. Pharm. Pharmacol. 2006, 58, 1183-1191.
17. Z-G. Gao, H-G. Choi, H-J. Shin, K-M. Park, S-J. Lim, C-K. Kim., "Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporin A", Int. J. Pharm., 1998, 161, 75-86. (Pubitemid 28080661)
18. Abdalla A, Mader K. "Preparation and characterization of a self emulsifying pellets formulation", Eur. J. Pharm Biopharm. 2007, 66:220-226. (Pubitemid 46654779)
19. S. Gumaste, D. Dalrymple, A. Serajuddin, "Development of lipid-based self-emulsifying tablets with Neusilin US2: Design consideration". AAPS Northeast Regional Discussion Group, Rocky Hill, CT (April 2012).
20. J. F. Cuine, J. C. L. McEvoy, W. N. Charman, C. W. Pouton, G. A. Edwards, H. Benameur, C. J. H. Porter, Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs, J. Pharm. Sci., 2008, 97, 995-1022.
21. C. J. H. Porter, N. L. Trevaskis, W. N. Charman, "Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs." Nature Reviews Drug Discovery 2007, 6, 231-248. (Pubitemid 46344627)
22. Y. Jiao, N. Ubrich, M. Marchand-Arvier, C. Vigneron, M. Hoffman, T. Lecompte, and P. Maincent. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits, Circulation 105:230-235 (2002). (Pubitemid 34084324)
23. M. Aprahamian, C. Michel, W. Humbert, J. P. Devissaguet, and C. Damge. Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. Biol. Cell 61:69-76 (1987). (Pubitemid 18046633)
24. S. M. Caliph, W. N. Charman, and C. J. Porter. "Effect of short-, medium-, and long-chain fatty acidbased vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymphcannulated and non-cannulated rats", J. Pharm. Sci. 2000, 89:1073-1084.
25. Fatouros, D. G., Karpf, D. M., Nielsen, F. S., Mullertz, A., Clinical studies with orl lipid-based formulations of poorly soluble compounds, Therapeut. Clin. Risk Manag., 2007, 3, 591-604. (Pubitemid 47496964)
26. B. E. Padden, J. M. Miller, T. Robbins, P. D. Zocharski, L. Prasad, J. K. Spence, J. LaFountaine, "Amorphous solid dispersions as enabling formulation for discovery and early development", Am. Pharma. Rev., 2011, Jan/Feb. 66-73.
27. J. C. DiNunzio, C. Brough, D. A. Miller, R. O. Williams III, J. W. McGinity, "Applications of KinetiSol dispersing for the production of plasticizer free amorphous solid dispersions", Eur. J. Pharm. Sci. 2010, 40, 179-187
28. M. Moneghini, N. De Zordi, D. Solinas, S. Macchiavelli, F. Princivalle, "Characterization of solid dispersions of itraconazole and vitamin E TPGS prepared by microwave technology", Future Med. Chem. 2010, 2, 237-246.
29. (a) S. Ali, N. Langley, D. Djuric, K. Kolter, S. Mirza, "Electrospinning for Solid Dispersions of Poorly Soluble Drugs", CRS 2011;
30. (b) Z. K. Nagy, A. Balogh, B. Vajna, A. Farkas, G. Patyi, 2A. Kramarics, G. Marosi, "Comparison of electrospun and extruded Soluplus-based solid dosage forms of improved dissolution", J. Pharm. Sci., 2011, 1-14 (DOI 10.1002/jps.22731)
31. K. C. Waterman, "Accelerated stability assessment program (ASAP): Using science to set shelf life", Pharm. Outsourcing, 2012, 40-46.
32. K. Dhirendra. S. Lewis, N. Udupa, K. Atin, "Solid dispersions: A Review, Pak. J. Pharm. Sci., 2009, 22, 234-246.
33. Y. S. R. Krishnaiah, "Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs". J Bioequiv Availab., 2010, 2, 28-36.
34. F. Qian, J. Huang, Q. Zhu, R. Haddadin, J. Gawal, R. Garmise, M. Hussain, "Is a distinctive singe Tg a reliable indicator for the homogeneity of amorphous solid dispersion?, Int. J. Pharm., 2010, 395, 232-235.
35. M. A. Repka, "Hot melt extrusion", Am. Pharm. Rev. 2009, 18-27.
36. C. A. McKelvey, "Design of stable extruded solid dispersions". CRS July 9, 2010, Educational Workshop 2, Portland, Oregon.
37. K. Kolter, M. Karl, S. Nalawade, N. Rottmann, "Hot melt extrusion with BASF pharma polymers: Extrusion Compendium, Oct. 2010.
38. D. Smithey, J. Fennewald, J. Gautschi, M. Crew, S. Ali, Y. Lan, and N. Langley, "Evaluation of the Polymer Soluplus for Spray-Dried Dispersions of Poorly Soluble Compounds", AAPS 2010.
39. Soluplus - Technical Brochure, BASF 2009.
40. S. Ali, N. Langley, D. Djuric, K. Kolter, "Soluplus-a novel polymer for hot melt extrusion, Tablets & Capsules, October 2010.
41. H. Hardung, D. Djuric, S. Ali, "Combining HME and Solubilization: Soluplus - The Solid Solution", Drug Del. Tech., 2010.
42. B. C. Hancock, M. Park, "What is the true solubility advantage of the different forms", Pharm. Res. 2000, 17, 397-404. (Pubitemid 30395293)
43. D. E. Alonzo, G. G. Z. Zhang, D. Zhou, Y. Gao, L. S. Taylor, "Understanding the behavior of amorphous pharmaceutical systems during dissolution", 2010, 27, 608-618.
44. J. C. DeNunzio, "Melt Extrusion: Technology Overview and Applications for Early Stage Formulation Development", IPRIME Workshop, University of Minnesota, Jan. 2012.
45. D. A. Miller, "APV/AAPS conference on hot melt extrusion", April 2011.
46. K. Six, G. Verreck, J. Peeters, M. Brewster, G. V. D. Mooter, "Increased physical stability and improved dissolution properties of itraconazole, a Class II drug, by solid dispersions that combine fast-and slow-dissolving polymers", J. Pharm. Sci., 2004, 93, 124-131. (Pubitemid 38081820)
47. K. Tsinman, O. Tsinman, N. Langley, and S. Ali, "Soluplus Maintains the Supersaturation of Carbamazepine from Amorphous Solid Solutions/Dispersions. " AAPS (2012).